Navigation Links
Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling
Date:4/14/2008

Data presented at AACR 2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Systems Medicine LLC (SM), a wholly owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC), presented data from a preclinical study demonstrating that the Company's experimental drug candidate, brostallicin, killed colon and ovarian cancer cells regardless of their p53 status. The study, conducted by Cristina Geroni, Ph.D., et al of Nerviano Medical Sciences in Milan, Italy suggests that while brostallicin is more effective in cells with normal p53 status, cells with abnormal or missing p53 are also killed when treated. P53 is a protein that regulates the cell cycle and acts as a tumor suppressor. Patient tumors that have low or absent p53 are less responsive to standard therapy and have a worse prognosis.

"The results of this study support the further clinical development of brostallicin. They also provide deeper insight into brostallicin's context of vulnerability concerning different types of p53 protein, and where it is most effective. In our continued efforts to make cancer more treatable, results like these increase our understanding of cancer and potential therapies, and bring us closer to being able to offer the right drugs to the right patients," said Jeffrey Jacob, CEO of SM.

This study examined brostallicin's effect on cell viability, cell cycle modulation, and the initiation of cell death in cancer cell models with either normal (also referred to as wild-type) or abnormal (mutated or absent) p53 tumor suppressor. These results were supported through tests in animal models, where brostallicin demonstrated a statistically significant effect on suppressing tumor growth. To review the poster and see more detailed information about the study, please go to http://www.celltherapeutics.com/investors_news-updates.htm.

About Brostall
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...AN DIEGO, Dec. 1 ADVENTR...nnounced that a new, recently completed preclinica...able toxicity of ANX-514 and Taxotere® (docet...tner for ANX-514 in South Korea, independently con...ndependent confirmation of the bioequivalence and ...
(Date:12/1/2009)...BRIDGEWATER, N.J., Dec. 1 Tibotec ... Products, L.P., announced today that it is launch...affecting women and people of color living with HI... local educational events, media outreach and a ne...s sharing learnings from the GRACE study, the larg...
(Date:12/1/2009)...OCKVILLE, Md., Dec. 1 Va...d today that the waiting period has expired under ... Act of 1976 with respect to Vanda,s agreement, da... that the agreement is now effective. Expiration ...ness of the agreement, triggers an upfront payment...
Breaking Medicine Technology:ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 2ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 3Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 2Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 3Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 4Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 5Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 6Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 7Hereditary Angioedema Patients Report 3A C1 Esterase Inhibitor Concentrate Effective in Treating Acute Attacks Helps Them Avoid Emergency Care 6070 1Hereditary Angioedema Patients Report 3A C1 Esterase Inhibitor Concentrate Effective in Treating Acute Attacks Helps Them Avoid Emergency Care 6070 2Hereditary Angioedema Patients Report 3A C1 Esterase Inhibitor Concentrate Effective in Treating Acute Attacks Helps Them Avoid Emergency Care 6070 3Bad Behaving Teens May Be Living Up to Expectations 60892 1Bad Behaving Teens May Be Living Up to Expectations 60892 2Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 60890 1Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 60890 2Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 60890 3
...c. 18 Medarex, Inc.,(Nasdaq: MEDX ) today announ...n undisclosed amount from its licensing partner, A...l trials. The antibody was developed using,Medarex...derived antibody,in clinical development by Amgen,...ical studies. Medarex may receive future milestone...
.... 17 Novavax, Inc.,(Nasdaq: NVAX ) announced tod...ts recombinant trivalent seasonal influenza virus-...l influenza vaccine is the second of two,influenza... its recombinant,VLP technology. The Company,s pan...Phase I/IIa clinical trials., In a study using mi...
Other Medicine Technology:Medarex to Receive Milestone Payment from Amgen 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 3
(Date:12/1/2009)...ON, Dec. 1 With employee...number of employers are providing self-service dec...nt season, according to a new survey by Watson Wya...f employers who offer these tools believe they lea...s. ,, According to the survey, 45 percent of co...
(Date:12/1/2009)...ITY, Dec. 1 The government of Mexi...s center for biomedical and nanomedical research, ...al research and development will be integrated wit...e top Spanish speaking university in the world. T...on in 2010, has been designed by the international...
(Date:12/1/2009)...INGTON, Dec. 1 On Decem...d 1,538 federal prisoners were HIV positive or had...(BJS) in the Office of Justice Programs, U.S. Depa...8, an estimated 5,672 inmates in state and federal...07. In 2007, about 43 per 10,000 prison inmates we...
(Date:12/1/2009)...D, Mich., Dec. 1 First ...rst Mercury" or the "Company") announced today tha...ared a quarterly cash dividend of $0.025 per share...record at the close of business on December 15, 20...tion ,, First Mercury Financial Corporation pr...
(Date:12/1/2009)... Central and South America, study finds , ...ercent of intensive care unit patients worldwide s...ng in the hospital, a new study finds. , Resear... 8, 2007) on 13,796 patients, aged 18 and older, i...ercent of patients were classified as infected and...
Breaking Medicine News(10 mins):Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 3Health News:Mexico City to Build World-Class Hub for Medical Research 2Health News:Rate of Confirmed AIDS in Prison 2.5 Times the Rate in the U.S. General Population 2Health News:Rate of Confirmed AIDS in Prison 2.5 Times the Rate in the U.S. General Population 3Health News:Half of ICU Patients Suffer From Infections 2
...lue Cross announced today that it is making a $10,...id to Californians in the Santa Barbara area who h...s to burn and threaten homes. , , In addition, A...rs may have left their homes without their prescri...
...o, medical blogger and health 2.0 consultant, publ...g medical and scientific videos and animations. T...tes from the best quality. Some of the sites are c...onals where they can upload their own videos or di...
...complications, study finds , , FRIDAY, May...kely than any other racial group to suffer serious...to require repeat procedures, but the reasons for ...ervention (PCI) procedure at Cook County Hospital ...
...uninsured American families who are not covered by... afford to buy health insurance, according to a ne... Quality. , , Some experts have suggested that be...ine, they can afford to purchase policies if they ...
...Available on Online Community to Facilitate Collab...evice Technologies , , FERNANDINA BEACH, Fla., Ma...st a few short weeks since launch, e-Zassi.com has...ew medical device technologies. And, to address t...
...ed Health Centers" Essential to Easing Health Care...re Able to Triple Number of Patients Aided. , , W...s on fixing health insurance without dealing with ...fully involved in health care reform, according to...
Other Medicine News:Health News:Anthem Blue Cross to Support Members and Communities Impacted by Santa Barbara Fires 2Health News:Racial Disparity Seen in Angioplasty Outcomes 2Health News:New Study Finds Fewer Families Can Afford Health Insurance 2Health News:New Advanced Search and Matching Function Drives e-Zassi.com's Enhanced Functionality 2Health News:University of Miami President Donna E. Shalala, Pennsylvania Gov. Edward G. Rendell: Nurse Practitioners Are Key to Obama Health Care Reform, Call for Increased Federal Funding for Innovative Nurse-Managed Health Care 2Health News:University of Miami President Donna E. Shalala, Pennsylvania Gov. Edward G. Rendell: Nurse Practitioners Are Key to Obama Health Care Reform, Call for Increased Federal Funding for Innovative Nurse-Managed Health Care 3Health News:University of Miami President Donna E. Shalala, Pennsylvania Gov. Edward G. Rendell: Nurse Practitioners Are Key to Obama Health Care Reform, Call for Increased Federal Funding for Innovative Nurse-Managed Health Care 4Health News:University of Miami President Donna E. Shalala, Pennsylvania Gov. Edward G. Rendell: Nurse Practitioners Are Key to Obama Health Care Reform, Call for Increased Federal Funding for Innovative Nurse-Managed Health Care 5Health News:University of Miami President Donna E. Shalala, Pennsylvania Gov. Edward G. Rendell: Nurse Practitioners Are Key to Obama Health Care Reform, Call for Increased Federal Funding for Innovative Nurse-Managed Health Care 6
Cryotherm Neck Wrap
DuraKold Back wrap and Wrist/Elbow
Cryotherm Shoulder Wrap
DuraKold Shoulder Wrap
Medicine Products: